Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Acorda Therapeutics (ACOR) Alert: Shareholder Rights Law Firm J&W Investigates Acorda Therapeutics, Inc.; Encourages Investors to Contact the Firm

PR Newswire August 30, 2017

Acorda Therapeutics, Inc. Investor Alert: Legal Investigation for Potential Securities Law Violations

Business Wire August 29, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Acorda Therapeutics, Inc.

Business Wire August 29, 2017

Mid-Afternoon Market Update: U.S. Stocks Turn Higher; J.Jill Shares Plummet

Benzinga.com  August 29, 2017

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

Business Wire August 29, 2017

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  August 29, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ellie Mae, Inc. - ELLI

PR Newswire August 29, 2017

Mid-Day Market Update: Movado Rises After Strong Q2 Results; Finish Line Shares Slide

Benzinga.com  August 29, 2017

INVESTOR ALERT: Investigation of Acorda Therapeutics Announced by Holzer & Holzer

Business Wire August 29, 2017

Mid-Morning Market Update: Markets Open Lower; Best Buy Tops Q2 Estimates

Benzinga.com  August 29, 2017

25 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  August 29, 2017

Acorda Receives Refusal to File Letter from FDA for INBRIJA™ (CVT-301, levodopa inhalation powder) New Drug Application

Business Wire August 29, 2017

Activists Gonna Activate: Hedge Funds Send Letters To Acorda, Taubman Centers Boards

Benzinga.com  August 7, 2017

18 Biggest Mid-Day Gainers For Monday

Benzinga.com  August 7, 2017

Acorda Provides Financial and Pipeline Update for Second Quarter 2017

Business Wire July 27, 2017

Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled for July 27, 2017

Business Wire July 13, 2017

Stocks Under Scanner in the Biotech Space -- Achillion Pharma, Kite Pharma, Acorda Therapeutics, and Tesaro

PR Newswire July 6, 2017

Acorda Submits New Drug Application to U.S. Food and Drug Administration for INBRIJATM (CVT-301, Levodopa Inhalation Powder)

Business Wire June 29, 2017

22 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  June 6, 2017

Acorda Presenting New Tozadenant Data at 2017 MDS Congress

Business Wire June 6, 2017